PGL 2

Drug Profile

PGL 2

Alternative Names: E2MATE; Estradiol sulfamate; Estradiol-3-O-sulfamate; J 995 - PregLem; J-995; PGL-2001; ZK-190628

Latest Information Update: 17 Jun 2015

Price : $50

At a glance

  • Originator Jenapharm
  • Developer PregLem
  • Class Estradiol congeners
  • Mechanism of Action Steryl sulfatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometriosis

Most Recent Events

  • 17 Jun 2015 PGL 2 (PGL2001) is still in phase-IIa development for Endometriosis in Europe
  • 01 May 2014 PregLem completes the phase II AMBER trial in Endometriosis (Combination therapy) in Hungary, Poland and Germany (NCT01631981)
  • 17 May 2013 PregLem completes enrolment in the phase II AMBER trial for Endometriosis in Hungary, Poland & Romania (NCT01631981)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top